
<TR><TD>Z</TD><TD>CYP3A5 CONTROLS FORMATION OF PARA HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_1026, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A5 CONTROLS FORMATION OF ORTHO HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_1236, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A5 CONTROLS FORMATION OF ALPHA HYDROXYALPRAZOLAM</TD><TD>BC SATISFIED ASSERTION_823, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A5 CONTROLS FORMATION OF 4 HYDROXYMIDAZOLAM</TD><TD>BC SATISFIED ASSERTION_490, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A5 CONTROLS FORMATION OF 4 HYDROXYALPRAZOLAM</TD><TD>BC SATISFIED ASSERTION_277, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A5 CONTROLS FORMATION OF 1PRIME HYDROXYMIDAZOLAM</TD><TD>BC SATISFIED ASSERTION_558, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF ZIPRASIDONE SULPHOXIDE</TD><TD>BC SATISFIED ASSERTION_225, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF PARA HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_639, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF ORTHO HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_301, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF ALPHA HYDROXYALPRAZOLAM</TD><TD>BC SATISFIED ASSERTION_623, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF 4 HYDROXYMIDAZOLAM</TD><TD>BC SATISFIED ASSERTION_460, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF 4 HYDROXYALPRAZOLAM</TD><TD>BC SATISFIED ASSERTION_707, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF 1PRIME HYDROXYMIDAZOLAM</TD><TD>BC SATISFIED ASSERTION_149, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_28, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP1,3 DIMETHYLURIC ACIDE1 CONTROLS FORMATION OF 1,3 DIMETHYLURIC ACID</TD><TD>BC SATISFIED ASSERTION_175, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP9 HYDROXYRISPERIDONED6 CONTROLS FORMATION OF 9 HYDROXYRISPERIDONE</TD><TD>BC SATISFIED ASSERTION_996, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP4 HYDROXYATOMOXETINED6 CONTROLS FORMATION OF 4 HYDROXYATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_304, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLROSUVASTATINC9 CONTROLS FORMATION OF N DESMETHYLROSUVASTATIN</TD><TD>BC SATISFIED ASSERTION_244, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DEALKYLPERPHENAZINEC9 CONTROLS FORMATION OF N DEALKYLPERPHENAZINE</TD><TD>BC SATISFIED ASSERTION_1199, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DEALKYLPERPHENAZINEC8 CONTROLS FORMATION OF N DEALKYLPERPHENAZINE</TD><TD>BC SATISFIED ASSERTION_76, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP6ALPHA HYDROXY PACLITAXELC8 CONTROLS FORMATION OF 6ALPHA HYDROXY PACLITAXEL</TD><TD>BC SATISFIED ASSERTION_1127, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLSERTRALINEC19 CONTROLS FORMATION OF N DESMETHYLSERTRALINE</TD><TD>BC SATISFIED ASSERTION_960, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLATOMOXETINEC19 CONTROLS FORMATION OF N DESMETHYLATOMOXETINE</TD><TD>BC SATISFIED ASSERTION_487, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DEALKYLPERPHENAZINEC19 CONTROLS FORMATION OF N DEALKYLPERPHENAZINE</TD><TD>BC SATISFIED ASSERTION_1202, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPHYDROXYBUPROPIONB6 CONTROLS FORMATION OF HYDROXYBUPROPION</TD><TD>BC SATISFIED ASSERTION_1186, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP1A3 METHYLXANTHINE CONTROLS FORMATION OF 3 METHYLXANTHINE</TD><TD>BC SATISFIED ASSERTION_264, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>CYP9 HYDROXYRISPERIDONED6 CONTROLS FORMATION OF 9 HYDROXYRISPERIDONE, RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>CYP3A4 CONTROLS FORMATION OF ORTHO HYDROXY ATORVASTATIN, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>CYP3A4 CONTROLS FORMATION OF PARA HYDROXY ATORVASTATIN, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5</TD><TD>CYP3A5 CONTROLS FORMATION OF ORTHO HYDROXY ATORVASTATIN, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5</TD><TD>CYP3A5 CONTROLS FORMATION OF PARA HYDROXY ATORVASTATIN, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, PAROXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, VERAPAMIL INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, VENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, VEMURAFENIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, TERBINAFINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, TELITHROMYCIN INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RITONAVIR INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RANOLAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, RANITIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, QUINIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, PROPAFENONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, PAZOPANIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, METHADONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, IMATINIB INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, ILOPERIDONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, HYDROXYCHLOROQUINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, HYDRALAZINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, FEBUXOSTAT INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DULOXETINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DIPHENHYDRAMINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DILTIAZEM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, DESVENLAFAXINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CLOBAZAM INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CINACALCET INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, CIMETIDINE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF RISPERIDONE TO 9 HYDROXYRISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, AMIODARONE INHIBITS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ZILEUTON INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, TELAPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, RANITIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, QUINIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, POSACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, PAZOPANIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, NILOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, NELFINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, LAPATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ISONIAZID INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, IMATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, FOSAMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, FLUVOXAMINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, FLUOXETINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ERYTHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, DRONEDARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, DILTIAZEM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CYCLOSPORINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CRIZOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CONIVAPTAN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CIPROFLOXACIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, BOCEPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, BICALUTAMIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, AZITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, APREPITANT INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, AMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ALPRAZOLAM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ZILEUTON INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, TELAPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, RANITIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, QUINIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, POSACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, PAZOPANIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, NILOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, NELFINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, LAPATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ISONIAZID INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, IMATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, FOSAMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, FLUVOXAMINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, FLUOXETINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ERYTHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, DRONEDARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, DILTIAZEM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CYCLOSPORINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CRIZOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CONIVAPTAN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CIPROFLOXACIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, BOCEPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, BICALUTAMIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, AZITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, APREPITANT INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, AMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ALPRAZOLAM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A5</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5, RANOLAZINE INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A5</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5, CLARITHROMYCIN INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO ORTHO HYDROXY ATORVASTATIN VIA CYP3A5</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5, ATAZANAVIR INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A5</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, RANOLAZINE INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A5</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, CLARITHROMYCIN INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS TRANSFORMATION OF ATORVASTATIN TO PARA HYDROXY ATORVASTATIN VIA CYP3A5</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, ATAZANAVIR INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF ZILEUTON REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ZILEUTON INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF ZAFIRLUKAST REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF VORICONAZOLE N OXIDE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF VORICONAZOLE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF VERAPAMIL REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF TELITHROMYCIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF TELAPREVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, TELAPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF RITONAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF RANOLAZINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF RANITIDINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, RANITIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF QUINIDINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, QUINIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF POSACONAZOLE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, POSACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF PAZOPANIB REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, PAZOPANIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF NILOTINIB REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, NILOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF NELFINAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, NELFINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF NEFAZODONE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF LAPATINIB REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, LAPATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF KETOCONAZOLE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF ITRACONAZOLE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF ISONIAZID REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ISONIAZID INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF INDINAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF IMATINIB REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, IMATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF FOSAMPRENAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, FOSAMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF FLUVOXAMINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, FLUVOXAMINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF FLUOXETINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, FLUOXETINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF FLUCONAZOLE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF ERYTHROMYCIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ERYTHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF DRONEDARONE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, DRONEDARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF DILTIAZEM REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, DILTIAZEM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF CYCLOSPORINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CYCLOSPORINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF CRIZOTINIB REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CRIZOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF CONIVAPTAN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CONIVAPTAN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF CLARITHROMYCIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF CIPROFLOXACIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CIPROFLOXACIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF CIMETIDINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF BOCEPREVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, BOCEPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF BICALUTAMIDE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, BICALUTAMIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF AZITHROMYCIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, AZITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF ATORVASTATIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF ATAZANAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF APREPITANT REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, APREPITANT INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF AMPRENAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, AMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF AMIODARONE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF ALPRAZOLAM REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ALPRAZOLAM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF ZILEUTON REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ZILEUTON INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF ZAFIRLUKAST REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ZAFIRLUKAST INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF VORICONAZOLE N OXIDE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, VORICONAZOLE N OXIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF VORICONAZOLE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, VORICONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF VERAPAMIL REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, VERAPAMIL INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF TELITHROMYCIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, TELITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF TELAPREVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, TELAPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF RITONAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, RITONAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF RANOLAZINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, RANOLAZINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF RANITIDINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, RANITIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF QUINIDINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, QUINIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF POSACONAZOLE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, POSACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF PAZOPANIB REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, PAZOPANIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF NILOTINIB REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, NILOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF NELFINAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, NELFINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF NEFAZODONE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, NEFAZODONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF LAPATINIB REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, LAPATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF KETOCONAZOLE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, KETOCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF ITRACONAZOLE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ITRACONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF ISONIAZID REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ISONIAZID INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF INDINAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, INDINAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF IMATINIB REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, IMATINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF FOSAMPRENAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, FOSAMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF FLUVOXAMINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, FLUVOXAMINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF FLUOXETINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, FLUOXETINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF FLUCONAZOLE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, FLUCONAZOLE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF ERYTHROMYCIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ERYTHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF DRONEDARONE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, DRONEDARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF DILTIAZEM REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, DILTIAZEM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF CYCLOSPORINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CYCLOSPORINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF CRIZOTINIB REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CRIZOTINIB INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF CONIVAPTAN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CONIVAPTAN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF CLARITHROMYCIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CLARITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF CIPROFLOXACIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CIPROFLOXACIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF CIMETIDINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, CIMETIDINE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF BOCEPREVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, BOCEPREVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF BICALUTAMIDE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, BICALUTAMIDE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF AZITHROMYCIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, AZITHROMYCIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF ATORVASTATIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF ATAZANAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ATAZANAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF APREPITANT REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, APREPITANT INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF AMPRENAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, AMPRENAVIR INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF AMIODARONE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, AMIODARONE INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF ALPRAZOLAM REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A4 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A4, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, ALPRAZOLAM INHIBITS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF RANOLAZINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A5 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5, RANOLAZINE INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF CLARITHROMYCIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A5 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5, CLARITHROMYCIN INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON ORTHO HYDROXY ATORVASTATIN OF ATAZANAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A5 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5, ATAZANAVIR INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF RANOLAZINE REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A5 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, RANOLAZINE INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF CLARITHROMYCIN REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A5 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, CLARITHROMYCIN INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFFECT ON PARA HYDROXY ATORVASTATIN OF ATAZANAVIR REDUCING THE CLEARANCE OF ATORVASTATIN VIA CYP3A5 IS AMBIGUOUS</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5, ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, ATAZANAVIR INHIBITS CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VALPROATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TROLEANDOMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIFLUOPERAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOPOTECAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLVAPTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIZANIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIGECYCLINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTHIXENE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTEPA IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIABENDAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TENIPOSIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TALINOLOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACROLIMUS IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULPHAPHENAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAMETHOXAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAMETHIZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SITAGLIPTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIROLIMUS IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SILDENAFIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SAXAGLIPTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SAQUINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RAMELTEON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINUPRISTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUININE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOXYPHENE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROMETHAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PRASUGREL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PITAVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PIOGLITAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYLPROPANOLAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXYCARBAZEPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXCARBAZEPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXANDROLONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NICARDIPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NEBIVOLOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MOLINDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIFEPRISTONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MEPHENYTOIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MELATONIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MARAVIROC IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LURASIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LITHIUM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IRINOTECAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>INDOMETHACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IBUPROFEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUTICASONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOROURACIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLECAINIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FEXOFENADINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FAMOTIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EZETIMIBE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EVEROLIMUS IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ETHANOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ELTROMBOPAG IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DROPERIDOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DOXORUBICIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIHYDROERGOTAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESLORATADINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESIPRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DELAVIRDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DASATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DARIFENACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DANAZOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN ETEXILATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COLCHICINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOTRIMAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOMIPRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPROMAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPHENIRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLOROQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORAMPHENICOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BASILIXIMAB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATRASENTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ASENAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMBRISENTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALOSETRON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALLOPURINOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALISKIREN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ACYCLOVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_590, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1423, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1388, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1426, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1387, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1422, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1421, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1386, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1420, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1440, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1399, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1439, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1385, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1417, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1416, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1398, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1414, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1415, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1412, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1392, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1384, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1409, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1408, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1407, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1406, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1395, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1383, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1391, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1403, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1382, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1400, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1437, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1424, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1436, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1418, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF ATORVASTATIN FOR CYP2C8 IS 0.019, ATORVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF ATORVASTATIN IS 2.52e 4 AT DOSE 0.08, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY LOVASTATIN FOR CYP2C8 IS 0.021, BETA HYDROXY LOVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF BETA HYDROXY LOVASTATIN IS 1.19e 5 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF FLUVASTATIN FOR CYP2C8 IS 0.008, FLUVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF FLUVASTATIN IS 4.0.04e 4 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF LOVASTATIN FOR CYP2C8 IS 0.003, LOVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF LOVASTATIN IS 7.8e 6 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_832, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1080, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_687, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_44, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_351, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_727, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1022, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_349, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1094, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_887, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1172, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_341, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_163, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1222, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_899, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_340, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_745, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_88, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_227, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_582, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_120, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1218, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_119, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_690, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1068, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_834, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_180, </TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_435, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_789, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_798, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_897, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_758, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_673, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_995, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_702, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_940, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_946, </TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_172, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_133, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_527, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_198, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_576, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_226, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1251, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_444, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_347, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_841, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_814, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1010, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1253, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1050, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_121, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1170, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS CYP2D6</TD><TD>PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1364, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1303, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_63, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_211, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_251, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_881, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_511, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1512, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_595, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_454, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1141, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1456, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1350, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1380, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1315, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1093, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1381, </TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1302, </TD></TR><BR>
<TR><TD>Z</TD><TD>TIGECYCLINE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1328, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1330, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1317, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1314, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1455, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1028, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1205, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1313, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_989, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1379, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1343, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1327, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_65, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_320, </TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN INHIBITS OATP1B3</TD><TD>BC SATISFIED ASSERTION_1500, </TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN INHIBITS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1483, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1454, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1151, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1152, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_369, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1363, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1378, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1453, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1508, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1032, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1377, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1311, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRASUGREL INHIBITS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1318, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1342, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1301, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1362, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1376, </TD></TR><BR>
<TR><TD>Z</TD><TD>OXANDROLONE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1321, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1333, </TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1310, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1361, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1341, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1513, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1195, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_688, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_287, </TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1320, </TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1326, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1300, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1375, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1511, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1360, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1458, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_630, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1338, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1452, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1158, </TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1359, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_486, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1349, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1374, </TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_296, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1373, </TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1372, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL INHIBITS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1482, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL INHIBITS CYP2C8</TD><TD>BC SATISFIED ASSERTION_1319, </TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1348, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1358, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_221, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1325, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1357, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1332, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_201, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1329, </TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1337, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1370, </TD></TR><BR>
<TR><TD>Z</TD><TD>FAMOTIDINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1309, </TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1324, </TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1336, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1331, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1459, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_111, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ELTROMBOPAG INHIBITS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1481, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_764, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1450, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1507, </TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1308, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1369, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1449, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_371, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1368, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1367, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1448, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS OATP1B3</TD><TD>BC SATISFIED ASSERTION_1499, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1480, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1356, </TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1347, </TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1323, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1447, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1340, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL INHIBITS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1316, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1365, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1446, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_714, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_713, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1346, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_313, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1057, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1514, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1355, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1366, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1335, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1307, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1322, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1306, </TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1339, </TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1353, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1457, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1510, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1015, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_241, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_242, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1334, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1345, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1344, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1443, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_695, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_404, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_403, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1250, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1351, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALLOPURINOL INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1305, </TD></TR><BR>
<TR><TD>Z</TD><TD>ACYCLOVIR INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1304, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, ATORVASTATIN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, ATORVASTATIN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, ATORVASTATIN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ACYCLOVIR INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ALLOPURINOL INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ALPRAZOLAM INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>AMIODARONE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>AMIODARONE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>AMIODARONE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>AMPRENAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>APREPITANT INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ARMODAFINIL INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ATORVASTATIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>AZITHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>AZITHROMYCIN INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>BICALUTAMIDE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>BOCEPREVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CAFFEINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CAPECITABINE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>CIMETIDINE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>CIMETIDINE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>CLARITHROMYCIN INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>CLOPIDOGREL INHIBITS CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CONIVAPTAN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>CONIVAPTAN INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CRIZOTINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CYCLOSPORINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, ROSUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF RIFAMPIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, RIFAMPIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, PRAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, PITAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, IRINOTECAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, FLUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, EZETIMIBE IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, ATRASENTAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B1</TD><TD>CYCLOSPORINE INHIBITS OATP1B1, ATORVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B3</TD><TD>CYCLOSPORINE INHIBITS OATP1B3, ROSUVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B3</TD><TD>CYCLOSPORINE INHIBITS OATP1B3, PITAVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B3</TD><TD>CYCLOSPORINE INHIBITS OATP1B3, ATORVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>CYCLOSPORINE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>DILTIAZEM INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>DILTIAZEM INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>DISULFIRAM INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>DRONEDARONE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>DRONEDARONE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, ROSUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF RIFAMPIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, RIFAMPIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, PRAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, PITAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, IRINOTECAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, FLUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, EZETIMIBE IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, ATRASENTAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ELTROMBOPAG INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B1</TD><TD>ELTROMBOPAG INHIBITS OATP1B1, ATORVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>ERYTHROMYCIN INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ETRAVIRINE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ETRAVIRINE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>FAMOTIDINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>FELBAMATE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>FLUCONAZOLE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>FLUOXETINE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FLUOXETINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUVASTATIN INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>FLUVOXAMINE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FLUVOXAMINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, ROSUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF RIFAMPIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, RIFAMPIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, PRAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, PITAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, IRINOTECAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, FLUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, EZETIMIBE IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, ATRASENTAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B1</TD><TD>GEMFIBROZIL INHIBITS OATP1B1, ATORVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>IMATINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ISONIAZID INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>ITRACONAZOLE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>KETOCONAZOLE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>LAPATINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>LAPATINIB INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>METHOXSALEN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>METRONIDAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>MICONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>MODAFINIL INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>NEFAZODONE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>NELFINAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>NILOTINIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>OXANDROLONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>PAZOPANIB INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>POSACONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>PRASUGREL INHIBITS CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>QUINIDINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>QUINIDINE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>RANITIDINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>RANOLAZINE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ZOLPIDEM VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, ZOLPIDEM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, TAMOXIFEN IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, RABEPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIRTAZAPINE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, MIRTAZAPINE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, LANSOPRAZOLE IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>RANOLAZINE INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>RANOLAZINE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF SIMVASTATIN ACID VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, ROSUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF PRAVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, PRAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, PITAVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF IRINOTECAN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, IRINOTECAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, FLUVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF EZETIMIBE VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, EZETIMIBE IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ATRASENTAN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, ATRASENTAN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B1</TD><TD>RIFAMPIN INHIBITS OATP1B1, ATORVASTATIN IS SUBSTRATE OF OATP1B1, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ROSUVASTATIN VIA OATP1B3</TD><TD>RIFAMPIN INHIBITS OATP1B3, ROSUVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF PITAVASTATIN VIA OATP1B3</TD><TD>RIFAMPIN INHIBITS OATP1B3, PITAVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RIFAMPIN INHIBITS METABOLIC CLEARANCE OF ATORVASTATIN VIA OATP1B3</TD><TD>RIFAMPIN INHIBITS OATP1B3, ATORVASTATIN IS SUBSTRATE OF OATP1B3, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>TELAPREVIR INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>TERBINAFINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICAGRELOR INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>TICAGRELOR INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>TICLOPIDINE INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, BUPROPION IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6</TD><TD>TICLOPIDINE INHIBITS CYP2B6, EFAVIRENZ IS SUBSTRATE OF CYP2B6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>TICLOPIDINE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TIGECYCLINE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VEMURAFENIB INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>VERAPAMIL INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>VORICONAZOLE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VORICONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FEXOFENADINE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF COLCHICINE VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>VORICONAZOLE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ZILEUTON INHIBITS CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>ZILEUTON INHIBITS CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MIDAZOLAM</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ACYCLOVIR INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>ACYCLOVIR INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALLOPURINOL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>ALLOPURINOL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ALPRAZOLAM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ALPRAZOLAM INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>AMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>APREPITANT INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>APREPITANT INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ARMODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ARMODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ARMODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>ARMODAFINIL INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATORVASTATIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ATORVASTATIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AZITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>AZITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BICALUTAMIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>BICALUTAMIDE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BOCEPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>BOCEPREVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAFFEINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CAFFEINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CAPECITABINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>CAPECITABINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CINACALCET INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>CINACALCET INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESIPRAMINE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOBAZAM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>CLOBAZAM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOPIDOGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF BUPROPION</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLOPIDOGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF EFAVIRENZ</TD><TD>CLOPIDOGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CONIVAPTAN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CONIVAPTAN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>COTRIMOXAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>COTRIMOXAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CRIZOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CRIZOTINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CYCLOSPORINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>CYCLOSPORINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DESVENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DILTIAZEM INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>DILTIAZEM INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TRIAZOLAM</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DIPHENHYDRAMINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DISULFIRAM INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>DISULFIRAM INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DRONEDARONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>DRONEDARONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>DULOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>DULOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ERYTHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ERYTHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ESOMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>ESOMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ETRAVIRINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>ETRAVIRINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FAMOTIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>FAMOTIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FEBUXOSTAT INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>FEBUXOSTAT INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FELBAMATE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FELBAMATE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FELBAMATE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>FELBAMATE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVASTATIN INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>FLUVASTATIN INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUVOXAMINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>FLUVOXAMINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FOSAMPRENAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>FOSAMPRENAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDRALAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>HYDRALAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>HYDROXYCHLOROQUINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ILOPERIDONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>ILOPERIDONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DEXTROMETHORPHAN</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>IMATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>IMATINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ISONIAZID INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ISONIAZID INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>LAPATINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>LAPATINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHADONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>METHADONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METHOXSALEN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>METHOXSALEN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>METRONIDAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>METRONIDAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>MICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>MODAFINIL INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MODAFINIL SULFONE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>MODAFINIL SULFONE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NELFINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>NELFINAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NILOTINIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>NILOTINIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OXANDROLONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>OXANDROLONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAZOPANIB INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>PAZOPANIB INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PHENYLPROPANOLAMINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>PHENYLPROPANOLAMINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>POSACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>POSACONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PRASUGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF BUPROPION</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PRASUGREL INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF EFAVIRENZ</TD><TD>PRASUGREL INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANITIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>RANITIDINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RANOLAZINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>RANOLAZINE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SULFINPYRAZONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>SULFINPYRAZONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELAPREVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>TELAPREVIR INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERIFLUNOMIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>TERIFLUNOMIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF BUPROPION</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF BUPROPION VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2B6 THE PRIMARY TOTAL CLEARANCE ENZ OF EFAVIRENZ</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF EFAVIRENZ VIA CYP2B6, PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TICLOPIDINE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>TICLOPIDINE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TIGECYCLINE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>TIGECYCLINE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VEMURAFENIB INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>VEMURAFENIB INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VENLAFAXINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>VENLAFAXINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>VORICONAZOLE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF OMEPRAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF LANSOPRAZOLE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF S MEPHENYTOIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VORICONAZOLE N OXIDE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>VORICONAZOLE N OXIDE INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZAFIRLUKAST INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ZAFIRLUKAST INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF CAFFEINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TIZANIDINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SILDENAFIL</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ZILEUTON INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF SIROLIMUS</TD><TD>ZILEUTON INHIBITS METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF ZAFIRLUKAST IS 0.04</TD><TD>BC SATISFIED ASSERTION_1233, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF VORICONAZOLE IS 0.2</TD><TD>BC SATISFIED ASSERTION_482, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF VALPROATE IS 0.5</TD><TD>BC SATISFIED ASSERTION_889, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TRIMETHOPRIM IS 0.2</TD><TD>BC SATISFIED ASSERTION_197, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TOPIRAMATE IS 0.025</TD><TD>BC SATISFIED ASSERTION_477, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TOLBUTAMIDE IS 0.25</TD><TD>BC SATISFIED ASSERTION_983, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF THEOPHYLLINE IS 0.84</TD><TD>BC SATISFIED ASSERTION_794, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF RANOLAZINE IS 1.0</TD><TD>BC SATISFIED ASSERTION_185, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PROPOXYPHENE IS 0.065</TD><TD>BC SATISFIED ASSERTION_1033, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PROMETHAZINE IS 0.0125</TD><TD>BC SATISFIED ASSERTION_998, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PANTOPRAZOLE IS 0.02</TD><TD>BC SATISFIED ASSERTION_622, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF NICARDIPINE IS 0.06</TD><TD>BC SATISFIED ASSERTION_754, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF MIDODRINE IS 0.03</TD><TD>BC SATISFIED ASSERTION_23, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF METRONIDAZOLE IS 0.75</TD><TD>BC SATISFIED ASSERTION_429, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF LEFLUNOMIDE IS 0.01</TD><TD>BC SATISFIED ASSERTION_1208, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF LANSOPRAZOLE IS 0.015</TD><TD>BC SATISFIED ASSERTION_1060, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF FLUVASTATIN IS 0.02</TD><TD>BC SATISFIED ASSERTION_935, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF CELECOXIB IS 0.2</TD><TD>BC SATISFIED ASSERTION_589, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF ATORVASTATIN IS 0.01</TD><TD>BC SATISFIED ASSERTION_368, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF ZAFIRLUKAST IS 0.04</TD><TD>BC SATISFIED ASSERTION_512, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF VORICONAZOLE IS 0.6</TD><TD>BC SATISFIED ASSERTION_599, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF VALPROATE IS 4.2</TD><TD>BC SATISFIED ASSERTION_317, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TRIMETHOPRIM IS 0.2</TD><TD>BC SATISFIED ASSERTION_214, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TOPIRAMATE IS 0.4</TD><TD>BC SATISFIED ASSERTION_1131, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TOLBUTAMIDE IS 3.0</TD><TD>BC SATISFIED ASSERTION_4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF THEOPHYLLINE IS 1.05</TD><TD>BC SATISFIED ASSERTION_647, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF RANOLAZINE IS 2.0</TD><TD>BC SATISFIED ASSERTION_505, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PROPOXYPHENE IS 0.6</TD><TD>BC SATISFIED ASSERTION_307, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PROMETHAZINE IS 0.15</TD><TD>BC SATISFIED ASSERTION_1150, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PANTOPRAZOLE IS 0.24</TD><TD>BC SATISFIED ASSERTION_738, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF NICARDIPINE IS 0.12</TD><TD>BC SATISFIED ASSERTION_135, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF MIDODRINE IS 0.04</TD><TD>BC SATISFIED ASSERTION_186, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF METRONIDAZOLE IS 4.0</TD><TD>BC SATISFIED ASSERTION_164, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF LEFLUNOMIDE IS 0.2</TD><TD>BC SATISFIED ASSERTION_924, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF LANSOPRAZOLE IS 0.18</TD><TD>BC SATISFIED ASSERTION_1008, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF FLUVASTATIN IS 0.8</TD><TD>BC SATISFIED ASSERTION_25, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF CELECOXIB IS 0.8</TD><TD>BC SATISFIED ASSERTION_967, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF ATORVASTATIN IS 0.08</TD><TD>BC SATISFIED ASSERTION_1089, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF SIMVASTATIN FOR CYP2C8 IS 0.003</TD><TD>BC SATISFIED ASSERTION_256, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF LOVASTATIN FOR CYP2C8 IS 0.003</TD><TD>BC SATISFIED ASSERTION_118, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUVASTATIN FOR CYP2C8 IS 0.008</TD><TD>BC SATISFIED ASSERTION_1105, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY SIMVASTATIN FOR CYP2C8 IS 0.018</TD><TD>BC SATISFIED ASSERTION_869, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY LOVASTATIN FOR CYP2C8 IS 0.021</TD><TD>BC SATISFIED ASSERTION_566, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ATORVASTATIN FOR CYP2C8 IS 0.019</TD><TD>BC SATISFIED ASSERTION_770, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS SUBSTRATE OF CYP2D6</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS SUBSTRATE OF CYP3A5</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESIPRAMINE IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALOSETRON IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS SUBSTRATE OF CYP2B6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DARIFENACIN IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DASATINIB IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ IS SUBSTRATE OF CYP2B6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>EVEROLIMUS IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUTICASONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>LURASIDONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MARAVIROC IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MELATONIN IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEBIVOLOL IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RAMELTEON IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>SILDENAFIL IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLVAPTAN IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_591, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_719, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_640, </TD></TR><BR>
<TR><TD>Z</TD><TD>WARFARIN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1396, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_298, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_547, </TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_383, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_654, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1479, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1478, </TD></TR><BR>
<TR><TD>Z</TD><TD>TIZANIDINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1390, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_895, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1389, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_796, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_957, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_580, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1169, </TD></TR><BR>
<TR><TD>Z</TD><TD>TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1477, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACROLIMUS IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1435, </TD></TR><BR>
<TR><TD>Z</TD><TD>SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1476, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1475, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIROLIMUS IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1434, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1491, </TD></TR><BR>
<TR><TD>Z</TD><TD>SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1474, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS SUBSTRATE OF OATP1B3</TD><TD>BC SATISFIED ASSERTION_1502, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1490, </TD></TR><BR>
<TR><TD>Z</TD><TD>RIFAMPIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1495, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1473, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1188, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_1129, </TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1228, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1433, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1493, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1472, </TD></TR><BR>
<TR><TD>Z</TD><TD>PITAVASTATIN IS SUBSTRATE OF OATP1B3</TD><TD>BC SATISFIED ASSERTION_1503, </TD></TR><BR>
<TR><TD>Z</TD><TD>PITAVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1492, </TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1432, </TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1442, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1397, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1002, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_533, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_254, </TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1394, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1471, </TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_152, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_1030, </TD></TR><BR>
<TR><TD>Z</TD><TD>MARAVIROC IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1470, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1469, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_890, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1206, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_838, </TD></TR><BR>
<TR><TD>Z</TD><TD>IRINOTECAN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1498, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1468, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1488, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_712, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_59, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_58, </TD></TR><BR>
<TR><TD>Z</TD><TD>FEXOFENADINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1467, </TD></TR><BR>
<TR><TD>Z</TD><TD>EZETIMIBE IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1487, </TD></TR><BR>
<TR><TD>Z</TD><TD>EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1466, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_181, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_127, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_700, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1429, </TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1464, </TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1463, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1428, </TD></TR><BR>
<TR><TD>Z</TD><TD>COLCHICINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1462, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_262, PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_966, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_856, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1019, </TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_194, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_239, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATRASENTAN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1484, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS SUBSTRATE OF OATP1B3</TD><TD>BC SATISFIED ASSERTION_1501, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>BC SATISFIED ASSERTION_1485, </TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_632, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1461, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_98, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1460, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1401, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_89, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM PERMANENTLY DEACTIVATES CATALYTIC FUNCTION OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_259, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE SULPHOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THREOHYDROBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE 5 SULFOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>REDUCED HALOPERIDOL IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE SULFOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORPROPOXYPHENE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLUOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXY HYDROCINNAMIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROCINNAMIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROHYDROBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESMETHYLCLOZAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESGLYMIDODRINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESACETYLDILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEHYDRO ARIPIPRAZOLE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BENZISOTHIAZOLE SULPHOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BENZISOTHIAZOLE SULPHONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA NAPHTHOFLAVONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA HYDROXYALPRAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S ZOPICLONE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S METHYL DIHYDROZIPRASIDONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S N DESMETHYLZOPICLONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>O DESMETHYLVENLAFAXINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLVENLAFAXINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLTAMOXIFEN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLSERTRALINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLATOMOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDESACETYL DILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYL_ERYTHROMYCIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>M CHLOROPHENYLPIPERAZINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>9 HYDROXYRISPERIDONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXYPERPHENAZINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXYCLOZAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXY QUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXY N DESALKYL QUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME HYDROXYMETHYL SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME HYDROXY SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME EXOMETHYLENE SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME EXOMETHYLENE LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME BETA HYDROXY LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6BETA HYDROXYTESTOSTERONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYTRIAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYTAMOXIFIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYMIDAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYDEBRISOQUINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYATOMOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYALPRAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>3ALPHA HYDROXYPRAVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>3 METHYLXANTHINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1PRIME HYDROXYMIDAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>14 HYDROXYCLARITHROMYCIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>10 N GLUCURONIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLXANTHINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLURIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1,3 DIMETHYLURIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS ANCESTOR OF 9 HYDROXYRISPERIDONE</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE VIA CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS ANCESTOR OF ORTHO HYDROXY ATORVASTATIN</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN VIA CYP3A5, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS ANCESTOR OF PARA HYDROXY ATORVASTATIN</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN VIA CYP3A5, </TD></TR><BR>
<TR><TD>(BC-SATISFIED 'ASSERTION_979)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_97)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_950)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_943)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_941)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_934)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_929)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_928)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_922)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_914)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_91)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_909)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_9)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_898)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_893)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_864)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_859)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_854)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_824)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_822)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_821)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_802)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_800)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_785)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_781)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_780)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_776)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_769)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_753)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_752)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_749)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_740)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_739)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_736)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_728)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_725)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_721)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_720)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_708)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_703)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_70)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_691)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_689)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_686)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_677)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_676)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_670)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_643)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_625)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_619)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_616)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_615)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_613)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_611)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_608)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_602)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_592)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_579)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_577)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_573)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_571)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_569)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_568)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_562)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_560)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_559)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_557)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_552)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_546)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_543)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_536)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_532)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_508)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_503)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_494)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_493)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_483)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_480)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_48)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_472)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_47)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_469)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_465)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_45)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_448)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_446)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_443)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_442)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_440)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_434)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_430)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_425)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_422)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_421)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_416)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_41)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_409)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_407)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_396)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_388)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_376)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_373)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_367)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_364)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_36)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_354)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_344)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_33)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_322)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_316)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_314)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_302)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_30)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_297)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_295)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_293)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_29)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_265)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_26)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_252)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_240)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_206)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_187)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_177)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_176)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_155)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_154)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_148)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_144)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_142)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_139)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_138)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1298)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1297)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1296)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1295)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1294)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1292)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1290)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_129)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1289)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1288)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1287)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1286)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1285)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1284)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1281)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1279)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1278)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1277)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1273)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1267)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1266)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1243)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1230)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1227)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1225)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1223)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1217)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1215)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1212)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1201)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1197)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1171)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1164)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_116)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1157)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1155)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1153)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1143)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1112)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1107)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1106)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1100)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_110)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1088)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1087)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1078)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1077)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_107)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1067)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1055)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1053)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1044)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1040)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_103)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1029)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1007)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1003)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_645)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_10)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_644)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1424)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1423)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1388)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1426)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1387)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1422)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1421)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1386)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1420)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1440)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1399)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1439)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1418)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1385)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1417)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1416)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1398)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1414)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1415)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1412)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1392)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1384)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1409)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1437)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1436)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1408)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1407)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1406)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1395)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1383)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1391)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1403)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1382)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1400)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_816)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1013)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1122)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1047)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_219)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1233)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_482)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_889)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_197)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_477)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_983)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_794)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_185)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1033)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_998)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_622)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_754)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_23)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_429)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1208)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1060)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_935)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_589)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_368)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_512)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_599)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_317)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_214)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1131)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_4)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_647)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_505)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_307)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1150)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_738)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_135)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_186)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_164)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_924)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1008)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_25)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_967)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1089)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_813)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_698)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_126)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_275)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_867)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_884)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_267)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_464)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_605)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_541)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_466)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1219)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1232)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_655)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1017)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_104)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_594)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1179)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_806)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_844)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1023)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_514)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1085)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_518)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_455)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_921)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_131)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_153)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_788)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_624)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_423)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_629)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_224)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_865)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_312)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_942)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_101)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1148)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_741)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_49)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_880)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1126)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_256)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_118)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1105)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_869)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_566)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_770)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_694)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_912)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1025)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_666)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_495)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1091)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_151)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_628)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_290)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_66)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_846)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_348)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_762)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_678)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_581)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_674)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_894)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_420)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_467)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1220)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_664)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1162)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_402)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_8)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1063)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_637)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_631)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_259)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_591)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_719)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_640)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1396)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_298)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_547)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_383)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_654)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1479)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1478)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1390)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_895)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1389)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_796)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_957)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_580)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1169)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1477)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1435)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1476)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1475)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1434)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1491)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1474)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1502)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1490)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1495)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1473)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1188)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1129)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1228)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1433)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1493)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1472)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1503)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1492)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1432)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1442)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1397)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1002)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_533)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_254)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1394)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1471)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_152)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1030)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1470)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1469)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_890)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1206)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_838)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1498)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1468)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1488)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_712)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_59)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_58)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1467)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1487)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1466)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_181)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_127)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_700)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1429)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1464)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1463)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1428)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1462)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_262)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_966)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_856)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1019)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_194)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_239)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1484)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1501)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1485)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_632)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1461)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_98)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1460)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1401)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_89)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_669)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_128)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_692)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_590)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1364)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1303)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_63)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_211)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_251)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_881)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_511)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1512)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_595)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_454)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1141)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1456)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1350)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1380)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1315)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1093)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1381)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1302)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1328)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1330)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1317)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1314)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1455)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1028)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1205)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1313)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_989)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1379)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1343)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1327)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_65)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_320)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1500)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1483)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1454)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1151)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1152)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_369)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1363)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1378)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1453)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1508)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1032)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1377)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1311)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1318)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1342)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1301)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1362)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1376)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1321)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1333)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1310)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1361)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1341)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1513)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1195)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_688)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_287)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1320)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1326)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1300)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1375)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1511)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1360)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1458)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_630)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1338)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1452)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1158)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1359)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_486)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1349)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1374)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_296)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1373)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1372)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1482)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1319)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1348)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1358)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_221)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1325)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1357)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1332)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_201)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1329)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1337)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1370)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1309)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1324)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1336)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1331)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1459)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_111)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1481)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_764)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1450)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1507)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1308)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1369)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1449)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_371)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1368)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1367)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1448)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1499)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1480)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1356)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1347)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1323)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1447)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1340)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1316)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1365)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1446)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_714)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_713)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1346)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_313)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1057)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1514)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1355)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1366)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1335)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1307)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1322)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1306)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1339)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1353)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1457)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1510)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1015)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_241)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_242)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1334)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1345)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1344)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1443)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_695)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_404)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_403)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1250)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1351)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1305)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1304)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_735)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_305)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_635)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_766)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_850)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1252)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1006)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1042)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1259)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_848)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_978)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_971)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_289)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_901)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_46)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_535)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_832)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1080)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_687)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_44)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_351)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_727)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1022)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_349)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1094)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_887)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1172)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_341)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_163)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1222)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_899)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_340)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_745)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_88)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_227)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_582)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_120)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1218)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_119)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_690)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1068)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_834)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_180)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_435)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_789)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_798)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_897)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_758)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_673)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_995)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_702)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_940)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_946)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_172)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_133)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_527)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_198)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_576)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_226)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1251)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_444)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_347)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_841)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_814)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1010)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1253)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1050)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_121)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1170)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1026)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1236)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_823)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_490)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_277)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_558)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_225)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_639)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_301)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_623)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_460)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_707)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_149)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_28)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_175)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_996)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_304)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_244)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1199)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_76)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1127)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_960)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_487)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1202)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1186)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_264)</TD></TR>
<TR><TD>Z</TD><TD>PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_692, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_735, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE THIORIDAZINE 5 SULFOXIDE</TD><TD>BC SATISFIED ASSERTION_305, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE MESORIDAZINE</TD><TD>BC SATISFIED ASSERTION_635, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE</TD><TD>BC SATISFIED ASSERTION_766, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE QUETIAPINE SULFOXIDE</TD><TD>BC SATISFIED ASSERTION_850, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE 7 HYDROXY QUETIAPINE</TD><TD>BC SATISFIED ASSERTION_1252, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE 7 HYDROXY N DESALKYL QUETIAPINE</TD><TD>BC SATISFIED ASSERTION_1006, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE HAS METABOLITE 10 N GLUCURONIDE</TD><TD>BC SATISFIED ASSERTION_1042, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE DESACETYLDILTIAZEM</TD><TD>BC SATISFIED ASSERTION_1259, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE N DEMETHYLDILTIAZEM</TD><TD>BC SATISFIED ASSERTION_848, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE N DEMETHYLDESACETYL DILTIAZEM</TD><TD>BC SATISFIED ASSERTION_978, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE DESMETHYLCLOZAPINE</TD><TD>BC SATISFIED ASSERTION_971, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE CLOZAPINE N OXIDE</TD><TD>BC SATISFIED ASSERTION_289, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE 7 HYDROXYCLOZAPINE</TD><TD>BC SATISFIED ASSERTION_901, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_46, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_535, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_669, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_128, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ZALEPLON IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_694, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF VORICONAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_912, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF TRAZODONE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1025, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ROSUVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_666, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF RISPERIDONE IS HIGH</TD><TD>BC SATISFIED ASSERTION_495, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF RABEPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1091, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF PANTOPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_151, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF PALIPERIDONE IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_628, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF NICARDIPINE IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_290, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF MIRTAZAPINE IS MEDIUM HIGH</TD><TD>BC SATISFIED ASSERTION_66, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF MIDODRINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_846, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF LOVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_348, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF LANSOPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_762, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF INDOMETHACIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_678, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUVOXAMINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_581, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUVASTATIN IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_674, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUPHENAZINE IS LOW</TD><TD>BC SATISFIED ASSERTION_894, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUCONAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_420, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ESCITALOPRAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_467, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF DILTIAZEM IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_1220, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CLARITHROMYCIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_664, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CITALOPRAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_1162, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CHLORPROMAZINE IS LOW</TD><TD>BC SATISFIED ASSERTION_402, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ATORVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_8, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ATOMOXETINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1063, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ARIPIPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_637, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ALPRAZOLAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_631, </TD></TR><BR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ATORVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'BETA-HYDROXY-LOVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'BETA-HYDROXY-SIMVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'LOVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'SIMVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ZOLPIDEM IS 1.06e 4 AT DOSE 0.01</TD><TD>BC SATISFIED ASSERTION_813, ASSUMED EFFECTIVE DOSE OF ZOLPIDEM IS 0.01, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ZIPRASIDONE IS 1.0.1294e 4 AT DOSE 0.12</TD><TD>BC SATISFIED ASSERTION_698, ASSUMED EFFECTIVE DOSE OF ZIPRASIDONE IS 0.12, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF VORICONAZOLE IS 4.66e 4 AT DOSE 0.6</TD><TD>BC SATISFIED ASSERTION_275, ASSUMED EFFECTIVE DOSE OF VORICONAZOLE IS 0.6, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF VENLAFAXINE IS 0.45.90.45e 4 AT DOSE 0.45</TD><TD>BC SATISFIED ASSERTION_867, ASSUMED EFFECTIVE DOSE OF VENLAFAXINE IS 0.45, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF TRAZODONE IS 0.002 AT DOSE 0.1</TD><TD>BC SATISFIED ASSERTION_884, ASSUMED EFFECTIVE DOSE OF TRAZODONE IS 0.1, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF THREOHYDROBUPROPION IS 5.098e 4 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_267, ASSUMED EFFECTIVE DOSE OF THREOHYDROBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ROSUVASTATIN IS 1.88e 5 AT DOSE 0.01</TD><TD>BC SATISFIED ASSERTION_464, ASSUMED EFFECTIVE DOSE OF ROSUVASTATIN IS 0.01, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF RISPERIDONE IS 7.9e 5 AT DOSE 0.001</TD><TD>BC SATISFIED ASSERTION_605, ASSUMED EFFECTIVE DOSE OF RISPERIDONE IS 0.001, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF RANOLAZINE IS 2.6e 4 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_541, ASSUMED EFFECTIVE DOSE OF RANOLAZINE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004</TD><TD>BC SATISFIED ASSERTION_466, ASSUMED EFFECTIVE DOSE OF PERPHENAZINE IS 0.004, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF PANTOPRAZOLE IS 2.5e 4 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1219, ASSUMED EFFECTIVE DOSE OF PANTOPRAZOLE IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125</TD><TD>BC SATISFIED ASSERTION_1232, ASSUMED EFFECTIVE DOSE OF OLANZAPINE IS 0.0125, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF METRONIDAZOLE IS 0.004 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_655, ASSUMED EFFECTIVE DOSE OF METRONIDAZOLE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF LOVASTATIN IS 7.8e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1017, ASSUMED EFFECTIVE DOSE OF LOVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF LANSOPRAZOLE IS 0.004 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_104, ASSUMED EFFECTIVE DOSE OF LANSOPRAZOLE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF KETOCONAZOLE IS 0.002 AT DOSE 0.2</TD><TD>BC SATISFIED ASSERTION_594, ASSUMED EFFECTIVE DOSE OF KETOCONAZOLE IS 0.2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF HYDROXYBUPROPION IS 0.001 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_1179, ASSUMED EFFECTIVE DOSE OF HYDROXYBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUVASTATIN IS 4.0.04e 4 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_806, ASSUMED EFFECTIVE DOSE OF FLUVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUPHENAZINE IS 2.0.012e 6 AT DOSE 0.012</TD><TD>BC SATISFIED ASSERTION_844, ASSUMED EFFECTIVE DOSE OF FLUPHENAZINE IS 0.012, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1023, ASSUMED EFFECTIVE DOSE OF FLUOXETINE IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUCONAZOLE IS 0.007 AT DOSE 0.4</TD><TD>BC SATISFIED ASSERTION_514, ASSUMED EFFECTIVE DOSE OF FLUCONAZOLE IS 0.4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ESCITALOPRAM IS 5.002e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1085, ASSUMED EFFECTIVE DOSE OF ESCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ERYTHROHYDROBUPROPION IS 1.457e 4 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_518, ASSUMED EFFECTIVE DOSE OF ERYTHROHYDROBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF DILTIAZEM IS 6.067e 5 AT DOSE 0.12</TD><TD>BC SATISFIED ASSERTION_455, ASSUMED EFFECTIVE DOSE OF DILTIAZEM IS 0.12, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15</TD><TD>BC SATISFIED ASSERTION_921, ASSUMED EFFECTIVE DOSE OF CLOZAPINE IS 0.15, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CLARITHROMYCIN IS 0.00251 AT DOSE 0.5</TD><TD>BC SATISFIED ASSERTION_131, ASSUMED EFFECTIVE DOSE OF CLARITHROMYCIN IS 0.5, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CHLORPROMAZINE IS 0.1.79e 5 AT DOSE 0.1</TD><TD>BC SATISFIED ASSERTION_153, ASSUMED EFFECTIVE DOSE OF CHLORPROMAZINE IS 0.1, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CELECOXIB IS 7.05e 5 AT DOSE 0.2</TD><TD>BC SATISFIED ASSERTION_788, ASSUMED EFFECTIVE DOSE OF CELECOXIB IS 0.2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF BUPROPION IS 1.44e 4 AT DOSE 0.15</TD><TD>BC SATISFIED ASSERTION_624, ASSUMED EFFECTIVE DOSE OF BUPROPION IS 0.15, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF BETA HYDROXY LOVASTATIN IS 1.19e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_423, ASSUMED EFFECTIVE DOSE OF BETA HYDROXY LOVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ATORVASTATIN IS 2.52e 4 AT DOSE 0.08</TD><TD>BC SATISFIED ASSERTION_629, ASSUMED EFFECTIVE DOSE OF ATORVASTATIN IS 0.08, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ASENAPINE IS 4.e 6 AT DOSE 0.005</TD><TD>BC SATISFIED ASSERTION_224, ASSUMED EFFECTIVE DOSE OF ASENAPINE IS 0.005, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ARIPIPRAZOLE IS 4.52e 4 AT DOSE 0.03</TD><TD>BC SATISFIED ASSERTION_865, ASSUMED EFFECTIVE DOSE OF ARIPIPRAZOLE IS 0.03, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ALPRAZOLAM IS 0.003.7e 5 AT DOSE 0.003</TD><TD>BC SATISFIED ASSERTION_312, ASSUMED EFFECTIVE DOSE OF ALPRAZOLAM IS 0.003, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF S DIDEMETHYLCITALOPRAM IS 1.897e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_942, ASSUMED EFFECTIVE DOSE OF S DIDEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF S DEMETHYLCITALOPRAM IS 1.40.047e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_101, ASSUMED EFFECTIVE DOSE OF S DEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF R DIDEMETHYLCITALOPRAM IS 0.04.971e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1148, ASSUMED EFFECTIVE DOSE OF R DIDEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF R DEMETHYLCITALOPRAM IS 1.946e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_741, ASSUMED EFFECTIVE DOSE OF R DEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF O DESMETHYLVENLAFAXINE IS 6.86e 4 AT DOSE 0.45</TD><TD>BC SATISFIED ASSERTION_49, ASSUMED EFFECTIVE DOSE OF O DESMETHYLVENLAFAXINE IS 0.45, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF 7 HYDROXYPERPHENAZINE IS 5.09e 7 AT DOSE 0.004</TD><TD>BC SATISFIED ASSERTION_880, ASSUMED EFFECTIVE DOSE OF 7 HYDROXYPERPHENAZINE IS 0.004, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF 14 HYDROXYCLARITHROMYCIN IS 8.8e 4 AT DOSE 0.5</TD><TD>BC SATISFIED ASSERTION_1126, ASSUMED EFFECTIVE DOSE OF 14 HYDROXYCLARITHROMYCIN IS 0.5, </TD></TR><BR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ZOLPIDEM '0.01)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ZIPRASIDONE '0.12)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'VORICONAZOLE '0.6)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'VENLAFAXINE '0.45)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'TRAZODONE '0.1)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'THREOHYDROBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ROSUVASTATIN '0.01)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'RISPERIDONE '0.001)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'RANOLAZINE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'PERPHENAZINE '0.004)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'PANTOPRAZOLE '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'OLANZAPINE '0.0125)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'METRONIDAZOLE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'LOVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'LANSOPRAZOLE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'KETOCONAZOLE '0.2)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'HYDROXYBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUPHENAZINE '0.012)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUOXETINE '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUCONAZOLE '0.4)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ESCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ERYTHROHYDROBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'DILTIAZEM '0.12)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CLOZAPINE '0.15)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CLARITHROMYCIN '0.5)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CHLORPROMAZINE '0.1)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CELECOXIB '0.2)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'BUPROPION '0.15)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'BETA-HYDROXY-LOVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ATORVASTATIN '0.08)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ASENAPINE '0.005)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ARIPIPRAZOLE '0.03)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ALPRAZOLAM '0.003)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'S-DIDEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'S-DEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'R-DIDEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'R-DEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'O-DESMETHYLVENLAFAXINE '0.45)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 '7-HYDROXYPERPHENAZINE '0.004)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 '14-HYDROXYCLARITHROMYCIN '0.5)</TD></TR>
<TR><TD>Z</TD><TD>ORAL DOSE FRACTION ABSORBED OF ROSUVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_1047, </TD></TR><BR>
<TR><TD>Z</TD><TD>ORAL DOSE FRACTION ABSORBED OF CLARITHROMYCIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_219, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF ROSUVASTATIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_816, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF RISPERIDONE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1013, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY METABOLIC CLEARANCE ENZYME OF ALPRAZOLAM IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1122, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MIDAZOLAM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MIDAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DESIPRAMINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESIPRAMINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TRIAZOLAM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TRIAZOLAM IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DEXTROMETHORPHAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DEXTROMETHORPHAN IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF S MEPHENYTOIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S MEPHENYTOIN IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ALOSETRON IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF APREPITANT IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF BUPROPION IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CAFFEINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CAFFEINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CELECOXIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CONIVAPTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DARIFENACIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DASATINIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DRONEDARONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DULOXETINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF EFAVIRENZ IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF EVEROLIMUS IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUTICASONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF INDINAVIR IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LANSOPRAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LANSOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LURASIDONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MARAVIROC IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MELATONIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF NEBIVOLOL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF OMEPRAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF OMEPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PERPHENAZINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF QUETIAPINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RAMELTEON IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SILDENAFIL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SILDENAFIL IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SIROLIMUS IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIROLIMUS IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TACRINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TICAGRELOR IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TIZANIDINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TIZANIDINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOLVAPTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PRAVASTATIN IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_645, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF KETOCONAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_10, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATORVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_644, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ATORVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ATORVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>BETA HYDROXY SIMVASTATIN DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MIDAZOLAM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MIDAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESIPRAMINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, DESIPRAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DEXTROMETHORPHAN VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, DEXTROMETHORPHAN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THIORIDAZINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, THIORIDAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, TAMOXIFEN IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RANOLAZINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, RANOLAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PAROXETINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, PAROXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, DULOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, CLOZAPINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, CINACALCET IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ARIPIPRAZOLE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, ARIPIPRAZOLE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRAVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRAVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SIMVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>SIMVASTATIN DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRIAZOLAM VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TRIAZOLAM IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF EVEROLIMUS VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, EVEROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SILDENAFIL VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, SILDENAFIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLVAPTAN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TOLVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZALEPLON VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ZALEPLON IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, VORICONAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TRAZODONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TRAZODONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TAMOXIFEN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACROLIMUS VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TACROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SIROLIMUS VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, SIROLIMUS IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, PIMOZIDE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, PANTOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MODAFINIL VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MODAFINIL IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, LANSOPRAZOLE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, FLUVASTATIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ESZOPICLONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, ESZOPICLONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CINACALCET IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DESALKYLQUETIAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, N DESALKYLQUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CAFFEINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, CAFFEINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TIZANIDINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, TIZANIDINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF THEOPHYLLINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, THEOPHYLLINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CINACALCET VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, CINACALCET IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF OMEPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, OMEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, VORICONAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RABEPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, RABEPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LANSOPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, LANSOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CITALOPRAM VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, CITALOPRAM IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S MEPHENYTOIN VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, S MEPHENYTOIN IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ZAFIRLUKAST VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, ZAFIRLUKAST IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF WARFARIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF VORICONAZOLE VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, VORICONAZOLE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TAMOXIFEN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, TAMOXIFEN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, FLUVASTATIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CIMETIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>CIMETIDINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CINACALCET DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>CINACALCET INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOBAZAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOBAZAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>CLOBAZAM INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DESVENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DESVENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>DESVENLAFAXINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DILTIAZEM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DILTIAZEM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>DILTIAZEM INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DIPHENHYDRAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DIPHENHYDRAMINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>DIPHENHYDRAMINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DULOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>DULOXETINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FEBUXOSTAT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FEBUXOSTAT DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>FEBUXOSTAT INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDRALAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDRALAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>HYDRALAZINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDROXYCHLOROQUINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HYDROXYCHLOROQUINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>HYDROXYCHLOROQUINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ILOPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ILOPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>ILOPERIDONE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>IMATINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>IMATINIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>IMATINIB INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHADONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>METHADONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>METHADONE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAZOPANIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAZOPANIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>PAZOPANIB INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PROPAFENONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>PROPAFENONE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANITIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>RANITIDINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RANOLAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>RANOLAZINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RITONAVIR DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>RITONAVIR INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TELITHROMYCIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>TELITHROMYCIN INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VEMURAFENIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VEMURAFENIB DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>VEMURAFENIB INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>VENLAFAXINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VERAPAMIL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>VERAPAMIL INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CLOZAPINE N OXIDE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, CLOZAPINE N OXIDE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVASTATIN VIA CYP2C8</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8, FLUVASTATIN IS SUBSTRATE OF CYP2C8, </TD></TR><BR>